Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trinean to Appoint New Board Member

Published: Friday, May 02, 2014
Last Updated: Friday, May 02, 2014
Bookmark and Share
Company announced that it appointed Mr Chris van Ingen as independent board member.

“We are very pleased to be working with Chris van Ingen,” comments Philippe Stas, CEO of Trinean. "His broad experience in the life science instrumentation field will be valuable to bring Trinean in its next phase of expansion.” 

“Trinean’s fully integrated instrumentation platform offers excellent opportunities to automate and simplify many life sciences workflows”, Chris van Ingen adds, “and I am looking forward working with the Trinean board and management team.” 

Currently, Chris is a director of the Bruker corporation, the Promega corporation and ProteinSimple corporation. Previously, Mr. van Ingen was president of Agilent Technologies’ Bio-Analytical Measurement Group. Between 1977 and 2001, Mr. van Ingen held several senior management positions at Hewlett Packard, including Vice President of Sales and Marketing of the Chemical Analysis group.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trinean to be Awarded ISO 9001:2008 Certification
Certification awarded for Trinean’s Quality Management System.
Tuesday, February 03, 2015
Trinean to Enter into Global Supply Agreement with QIAGEN
Trinean to manufacture and supply the QIAxpert - a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.
Tuesday, January 21, 2014
Trinean Signs a Global Agreement with Bayer CropScience
Bayer will use Trinean’s technology for biomolecule QC using spectral content profiling.
Wednesday, June 12, 2013
Trinean Secures 1 Million Euro Financing
Capricorn Health-tech Fund to join the investor base.
Wednesday, May 29, 2013
Trinean Appoints New CEO and Secures 2.7 Million Euro Financing
Appointment of Philippe Stas as Company’s new CEO.
Monday, April 30, 2012
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!